Volume 14, Issue 2 (2-2016)                   IJRM 2016, 14(2): 81-88 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Al- Gareeb A, Abd Al- Amieer W S, M. Alkuraishy H, J. Al- Mayahi T. Effect of body weight on serum homocysteine level in patients with polycystic ovarian syndrome: A case control study. IJRM 2016; 14 (2) :81-88
URL: http://ijrm.ir/article-1-726-en.html
Effect of body weight on serum homocysteine level in patients with polycystic ovarian syndrome: A case control study
Ali Al- Gareeb * 1, Wafaa Salah Abd Al- Amieer2 , Hayder M. Alkuraishy3 , Thabat J. Al- Mayahi4
1- Department of Clinical Pharmacology and Therapeutics, College of Medicine, Al- Mustansiriya University, Baghdad, Iraq , dr.alialgareeb78@yahoo.com
2- Department of Obstetrics and Gynecology, Al-Kadhymia Teaching Hospital, Baghdad, Iraq
3- Department of Clinical Pharmacology and Therapeutics, College of Medicine, Al- Mustansiriya University, Baghdad, Iraq
4- Department of Obstetrics and Gynecology, Al- Kadhymia Teaching Hospital, Baghdad, Iraq
Abstract:   (2566 Views)
Background: Polycystic ovarian syndrome (PCOS) represent one of the common endocrine disorders which influence around 8% of reproductive women whom usually suffering from obesity and increase cardiovascular risk. Serum homocysteine levels are associated with bad impact on endothelial functions and considered as an independent risk factor for cardiovascular disease.
Objective: The aim was to study the level of plasma homocysteine in obese and non-obese Iraqi patients with PCOS.
Materials and Methods: This study was carried out on 207 women. Of theme, 101 women with PCOS and 106 PCOS- free women served as controls. Blood sample was taken from each participant on the 2nd day of menstruation morning after an overnight fasting. Serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), free testosterone and androstenedione were measured. Moreover, total lipid profile and plasma homocysteine levels were measured in both groups.
Results: Sixty percent of PCOS women were overweight or obese and 56% of them had a waist circumference >88cm. Moreover plasma homocysteine concentrations were found to be higher in patients with PCOS (11.5±5.41μmol/L) as compared with control (8.10±1.89 μmol/L) (p<0.002). Furthermore the homocysteine concentrations were 13.19±5.97 μmol/L and 9.38±2.99 μmol/L in both obese and normal-weight PCOS women respectively which was significantly higher than obese (p<0.002) and normal-weight (p<0.004) control women.
Conclusion: Increase in body weight is not an independent risk factor to increase plasma homocysteine levels in PCOS women.
Keywords: Homocysteine, Body weight, Polycystic ovarian syndrome
Full-Text [PDF 188 kb]   (753 Downloads) |   |   Full-Text (HTML)  (408 Views)  
Type of Study: Original Article |
References
1. Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. J Med Life 2015; 8: 142-145.
2. Burt Solorzano CM, Beller JP, Abshire MY, Collins JS, McCartney CR, Marshall JC. Neuroendocrine dysfunction in polycystic ovary syndrome. Steroids 2012; 77: 332-337. [DOI:10.1016/j.steroids.2011.12.007]
3. Roland AV, Moenter SM. Reproductive neuroendocrine dysfunction in polycystic ovary syndrome: insight from animal models. Front Neuroendocrinol 2014; 35: 494-511. [DOI:10.1016/j.yfrne.2014.04.002]
4. Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am 2011; 95: 875-892. [DOI:10.1016/j.mcna.2011.06.002]
5. González F. Nutrient-Induced Inflammation in Polycystic Ovary Syndrome: Role in the Development of Metabolic Aberration and Ovarian Dysfunction. Semin Reprod Med 2015; 33: 276-286. [DOI:10.1055/s-0035-1554918]
6. Mukherjee S, Maitra A. Molecular, genetic factors contributing to insulin resistance in polycystic ovary syndrome. Indian J Med Res 2010; 131: 743-760
7. Gurda D, Handschuh L, Kotkowiak W, Jakubowski H. Homocysteine thiolactone and N-homocysteinylated protein induce pro-atherogenic changes in gene expression in human vascular endothelial cells. Amino Acids 2015; 47: 1319-1339. [DOI:10.1007/s00726-015-1956-7]
8. Prajapati J, Jain S, Virpariya K, Rawal J, Joshi H, Sharma K, et al. Novel atherosclerotic risk factors and angiographic profile of young Gujarati patients with acute coronary syndrome. J Assoc Phys Ind 2014; 62: 584-588.
9. Cao C, Hu J, Dong Y, Zhan R, Li P, Su H, et al. Gender differences in the risk factors for endothelial dysfunction in Chinese hypertensive patients: homocysteine is an independent risk factor in females. PLoS One 2015; 10: e0118686. [DOI:10.1371/journal.pone.0118686]
10. Papandreou D, Mavromichalis I, Makedou A, Rousso I, Arvanitidou M. Reference range of total serum homocysteine level and dietary indexes in healthy Greek schoolchildren aged 6-15 years. Br J Nutr 2006; 96: 719-724.
11. Feng SQ, Ye P, Luo LM, Xiao WK, Xu RY, Wu HM. Relationship between serum homocysteine and metabolic syndrome: A cross-sectional study. Zhonghua Liu Xing Bing Xue Za Zhi 2012; 33: 256-259.
12. Kang, SS, Wong PW, Malinow MR. Hyperhomocyst (e) inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992; 12: 279-298. [DOI:10.1146/annurev.nu.12.070192.001431]
13. Wilcken DE, Wilcken, B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest 1976; 57: 1079-1082. [DOI:10.1172/JCI108350]
14. Van Guldener C, Stehouwer CD. Hyperhomocysteinemia, vascular pathology, and endothelial dysfunction. Semin Thromb Hemost 2000; 26: 281-289. [DOI:10.1055/s-2000-8472]
15. Wong YY, Golledge J, Flicker L, McCaul KA, Hankey GJ, Van Bockxmeer FM et al. Plasma total homocysteine is associated with abdominal aortic aneurysm and aortic diameter in older men. J Vasc Surg 2013; 58: 364-370. [DOI:10.1016/j.jvs.2013.01.046]
16. Sule AA, Chin TJ, Khien LH. Recurrent unprovoked venous thromboembolism in a young female patient with high levels of homocysteine. Int J Angiol 2012; 21: 95-98. [DOI:10.1055/s-0032-1315626]
17. Chen H, Sun Y, Wang X, Si Q, Yao W, Wan Z. Association of cardiometabolic risk profile with prehypertensionaccompanyhyperhomocysteinaemia. Clin Exp Hypertens 2015; 37: 218-222. [DOI:10.3109/10641963.2014.939276]
18. Esmaeilzadeh S, Andarieh MG, Ghadimi R, Delavar MA. Body mass index and gonadotropin hormones (LH &, FSH) associate with clinical symptoms among women with polycystic ovary syndrome Glob J Health Sci 2014; 28: 101-106.
19. Diamanti- Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine Rev 2012; 33: 981-1030. [DOI:10.1210/er.2011-1034]
20. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47. [DOI:10.1093/humrep/deh098]
21. Refsum H, Hellimd S, Uelalid PM. Radioenzymje determination of homocyateine in plasma and urine. Clin Chem 1985; 31: 824-828.
22. Unluer AN, Findik RB, Sevinc N, Karakaya J. Comparison of HbA1c levels in obese and non-obese polycystic ovarian patients. Clin Exp Obstet Gynecol 2013; 40: 148-150.
23. Legro RS. Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 2012; 30: 496-506. [DOI:10.1055/s-0032-1328878]
24. Vague J. The degree of masculine differentiation of obesities: A factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr 1956; 4: 20- 34. [DOI:10.1093/ajcn/4.1.20]
25. Elbers JM, Asscheman H, Seidell JC, Megens JA, Gooren LJ. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab 1997; 82: 2044-2047. [DOI:10.1210/jc.82.7.2044]
26. Moran C, Arriaga M, Arechavaleta- Velasco F, Moran S. Adrenal androgen excess and body mass index in polycystic ovary syndrome. J Clin Endocrinol Metab 2015; 100: 942-950. [DOI:10.1210/jc.2014-2569]
27. Alexanderson C, Eriksson E, Stener- Victorin E, Lystig T, Gabrielsson B, Lönn M, Holmäng A. Postnatal testosterone exposure results in insulin resistance, enlarged mesenteric adipocytes, and an atherogenic lipid profile in adult female rats: comparisons with estradiol and dihydrotestosterone. Endocrinology 2007; 148: 5369-5376. [DOI:10.1210/en.2007-0305]
28. Harrison CL, Stepto NK, Hutchison SK, Teede HJ. Teede. The impact of intensified exercise training on insulin resistance and fitness in overweight and obese women with and without polycystic ovary syndrome. Clin Endocrinol 2012; 76: 351-357. [DOI:10.1111/j.1365-2265.2011.04160.x]
29. Li XJ, Yu YX, Liu CQ, Zhang W, Zhang HJ, Yan B et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol 2011; 74: 332-339. [DOI:10.1111/j.1365-2265.2010.03917.x]
30. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, et al. A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008; 93: 470-476. [DOI:10.1210/jc.2007-1756]
31. Huang J, Ni R, Chen X, Huang L, Mo Y, Yang D. Metabolic abnormalities in adolescents with polycystic ovary syndrome in south China. Reprod Biol Endocrinol 2010; 8: 142. [DOI:10.1186/1477-7827-8-142]
32. Dilbaz B, Ozkaya E, Cinar M, Cakir E, Dilbaz S. Cardiovascular disease risk characteristics of the main polycystic ovary syndrome phenotypes. Endocrine 2011; 39; 272-277. [DOI:10.1007/s12020-011-9437-6]
33. Boden G. Obesity, insulin resistance and free fatty acids. Cur Opin Endocrin Diabetes Obes 2011; 18: 139-143. [DOI:10.1097/MED.0b013e3283444b09]
34. Baldani DP, Skrgatić L, Goldstajn MS, Zlopasa G, Oguić SK, Canić T, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Croatian population. Coll Antropol 2012; 36: 1413-1418.
35. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245. [DOI:10.1210/jc.2006-0178]
36. Thornton EC, Von Wald T, Hansen K. Polycystic Ovarian Syndrome: A Primer. SD Med 2015; 68: 257-261.
37. Baldani DP, Skrgatic L, Ougouag R. Polycystic Ovary Syndrome: Important Underrecognised Cardiometabolic Risk Factor in Reproductive-Age Women. Int J Endocrinol 2015; 2015: 786362. [DOI:10.1155/2015/786362]
38. Feng SQ, Ye P, Luo LM, Xiao WK, Bai YY, Feng D, et al. Associations of plasma homocysteine and high-sensitivity C- reactive protein levels with arterial stiffness in Chinese population: a community- based study. Chin Med J (Engl) 2012; 125: 44-49.
39. Loverro G, Lorusso F, Mei L, Depalo R, Cormio G,Selvaggi L. The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest 2002; 53: 157-162. [DOI:10.1159/000058367]
40. Wijeyaratne CN, Nirantharakumar K, Balen AH, Barth JH, Sheriff R, Belchetz PE. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity. Clin Endocrinol 2004; 60: 560-567. [DOI:10.1111/j.1365-2265.2004.02019.x]
41. Mancini F, Cianciosi A, Reggiani GM, Facchinetti F, Battaglia C, de Aloysio D. Endothelial function and its relation- ship to leptin, homocysteine, and insulin resistance in lean and overweight eumenorrheic women and PCOS patients:a pilot study. Fertil Steril 2009; 91: 2537-2544. [DOI:10.1016/j.fertnstert.2008.03.023]
42. Maleedhu P, M V, SS BS, Kodumuri PK, Devi DV. Status of Homocysteine in Polycystic Ovary Syndrome (PCOS). J Clin Diagn Res 2014; 8: 31-33. [DOI:10.7860/JCDR/2014/7070.3999]
43. Ilhan T, Berrin C, Zeynep C, Erdem T. The Plasma homocysteine concentrations and relationship with insulin resistance in young women with polycystic ovary syndrome. Turk J Endocrinol Metab 2005; 1: 23-28.
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb